Bioavailability Study of Clonazepam Tablets Under Fasting Conditions

Exclusion Criteria

• •Subjects with a history of chronic alcohol consumption (during past 2 years), drug addiction, or serious gastrointestinal, renal, hepatic or cardiovascular disease, tuberculosis epilepsy, asthma, (during pat 5 years), diabetes, psychosis or glaucoma will not be eligible for this study.
• •Subjects whose clinical laboratory test values are outside the normal range may be retested at the discretion of the clinical investigator. If the clinical values are outside the range on retesting, the subject will not be eligible to participate in the study unless the clinical investigator deems the result to not be significant.
• •Subjects who have a history of allergic response to the class of drug being tested should excluded form the study.
• •All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and check in each dosing period. Subjects found to have urine concentration of any of the tested drugs will not be allowed to participate.
• •Subjects should not have donated blood and/plasma for at least thirty (30) days prior to the first dosing of the study
• •Subjects who have taken any investigational drug within thirty (30) days prior to the first dosing of the study will not be allowed to participate.
• •Female subjects with childbearing potential will not be allowed to participate.
• •All female subjects will be screened for pregnancy at check in each study period.